The latest price target for Lexeo Therapeutics (NASDAQ:LXEO) was reported by RBC Capital on January 21, 2025. The analyst firm set a price target for $24.00 expecting LXEO to rise to within 12 months (a possible 330.11% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for Lexeo Therapeutics (NASDAQ:LXEO) was provided by RBC Capital, and Lexeo Therapeutics reiterated their outperform rating.

There is no last upgrade for Lexeo Therapeutics

There is no last downgrade for Lexeo Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lexeo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lexeo Therapeutics was filed on January 21, 2025 so you should expect the next rating to be made available sometime around January 21, 2026.

While ratings are subjective and will change, the latest Lexeo Therapeutics (LXEO) rating was a reiterated with a price target of $24.00 to $24.00. The current price Lexeo Therapeutics (LXEO) is trading at is $5.58, which is out of the analyst’s predicted range.